Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading ASBP daily closes…
Loading price history…
Pipeline assets
High-dose sublingual aspirin
Stage not disclosed · ActiveModality: sublingual aspirin formulation
Aliases Instaprin
Indications
suspected acute myocardial infarction(Stage not disclosed)
Catalysts
— None
Status note No formal development phase stated. 505(b)(2) NDA timing stated inconsistently as first six months of 2027 and late 2026/early 2027; both statements preserved. Other named formulations (melatonin, vitamins, erectile-dysfunction, caffeine, meclizine, ondansetron, alprazolam, clopidogrel, microdose nicotine) are commercial supplements or merely contemplated formulations; no rows created.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.